Rifaximin vs no treatment for early blood protein disorder
Treatments studied
Part of Blood & lymphatic clinical trials.
This study tests whether an antibiotic called rifaximin can lower the abnormal protein levels in people with MGUS (a condition that can sometimes lead to blood cancers). If it works, it might help keep MGUS from getting worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a condition called MGUS — that means you have slightly higher levels of certain proteins (IgG or IgA) in your blood.
- If you can become pregnant, you must agree to use birth control during the study. Men must also use protection.
- You must not have taken any antibiotics in the 2 weeks before starting.
- You must not be pregnant, allergic to rifaximin, or receiving other experimental treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special label (carbon 13) to track bone marrow cells in people with a pre-cancer condition called MGUS. It aims to learn how these cells work, which may help understand the condition better.
This study compares the gut bacteria of healthy adults (age 45+) with those who have a blood condition called monoclonal gammopathy. The goal is to see if gut bacteria patterns differ between the two groups.
This study looks at how your gut bacteria (intestinal flora) and immune system relate to a condition called monoclonal gammopathy, where an abnormal protein is found in the blood. The trial will check samples from your blood, plasma, and stool to understand these connections.
This study tests how Rifaximin (a medicine for SIBO) affects the bacteria and other substances in your gut. You'll swallow a small capsule that collects samples as it travels through your digestive system, so researchers can see how your gut changes during treatment.
This study tests whether adding a medicine called rifaximin can help prevent diarrhea caused by radiation therapy for pelvic cancers. It may help you avoid a common and uncomfortable side effect during your cancer treatment.
This trial tests whether it is safe to stop or extend immunoglobulin (Ig) therapy for people with low antibody levels, or if switching to preventive antibiotics works just as well to prevent infections.
Hear when a new IgA Monoclonal Gammopathy of Undetermined Significance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.